Latest news with #Medifast
Yahoo
4 days ago
- Business
- Yahoo
Monday.com, Oxford Industries, and Medifast Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after the major indices rebounded (Nasdaq +1.5%, S&P 500 +1.0%) as reports pointed to easing tensions between Israel and Iran. The Wall Street Journal said senior Iranian officials had signaled a willingness to restart stalled nuclear talks, on the condition that Washington refrain from joining Israel's ongoing strikes. This development triggered a significant decline in oil prices, easing inflation concerns. Also, it is possible some investors were buying the dip following the sell-off at the end of the previous week. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Among others, the following stocks were impacted: Project Management Software company (NASDAQ:MNDY) jumped 5.2%. Is now the time to buy Access our full analysis report here, it's free. Apparel and Accessories company Oxford Industries (NYSE:OXM) jumped 5.1%. Is now the time to buy Oxford Industries? Access our full analysis report here, it's free. Personal Care company Medifast (NYSE:MED) jumped 5%. Is now the time to buy Medifast? Access our full analysis report here, it's free. shares are very volatile and have had 29 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 3 days ago when the stock dropped 5.4% on the news that the major indices pulled back (Nasdaq -1.3%, S&P 500 -1.1%) as Israel carried out significant strikes on Iranian nuclear and military sites, dramatically escalating fears of a broader conflict in the Middle East. This development sent crude oil prices surging, as investors feared potential disruptions to global oil supply and a wider regional conflict. is up 24.7% since the beginning of the year, but at $288 per share, it is still trading 12.2% below its 52-week high of $327.92 from February 2025. Investors who bought $1,000 worth of shares at the IPO in June 2021 would now be looking at an investment worth $1,610. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Business
- Yahoo
Monday.com, Oxford Industries, and Medifast Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after the major indices rebounded (Nasdaq +1.5%, S&P 500 +1.0%) as reports pointed to easing tensions between Israel and Iran. The Wall Street Journal said senior Iranian officials had signaled a willingness to restart stalled nuclear talks, on the condition that Washington refrain from joining Israel's ongoing strikes. This development triggered a significant decline in oil prices, easing inflation concerns. Also, it is possible some investors were buying the dip following the sell-off at the end of the previous week. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Among others, the following stocks were impacted: Project Management Software company (NASDAQ:MNDY) jumped 5.2%. Is now the time to buy Access our full analysis report here, it's free. Apparel and Accessories company Oxford Industries (NYSE:OXM) jumped 5.1%. Is now the time to buy Oxford Industries? Access our full analysis report here, it's free. Personal Care company Medifast (NYSE:MED) jumped 5%. Is now the time to buy Medifast? Access our full analysis report here, it's free. shares are very volatile and have had 29 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 3 days ago when the stock dropped 5.4% on the news that the major indices pulled back (Nasdaq -1.3%, S&P 500 -1.1%) as Israel carried out significant strikes on Iranian nuclear and military sites, dramatically escalating fears of a broader conflict in the Middle East. This development sent crude oil prices surging, as investors feared potential disruptions to global oil supply and a wider regional conflict. is up 24.7% since the beginning of the year, but at $288 per share, it is still trading 12.2% below its 52-week high of $327.92 from February 2025. Investors who bought $1,000 worth of shares at the IPO in June 2021 would now be looking at an investment worth $1,610. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13-06-2025
- Business
- Yahoo
1 Safe-and-Steady Stock on Our Watchlist and 2 to Question
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies. Luckily for you, StockStory helps you navigate which companies are truly worth holding. Keeping that in mind, here is one low-volatility stock that could succeed under all market conditions and two that may not deliver the returns you need. Rolling One-Year Beta: 0.22 Known for its Optavia program that combines portion-controlled meal replacements with coaching, Medifast (NYSE:MED) has a broad product portfolio of bars, snacks, drinks, and desserts for those looking to lose weight or consume healthier foods. Why Should You Dump MED? Products aren't resonating with the market as its revenue declined by 30.3% annually over the last three years Operating margin declined by 10.2 percentage points over the last year as its sales cratered Earnings per share have contracted by 27% annually over the last three years, a headwind for returns as stock prices often echo long-term EPS performance Medifast's stock price of $13.16 implies a valuation ratio of 0.4x forward price-to-sales. Dive into our free research report to see why there are better opportunities than MED. Rolling One-Year Beta: 0.77 Pioneering carbon-neutral flooring since its founding in 1973, Interface (NASDAQ:TILE) is a global manufacturer of modular carpet tiles, luxury vinyl tile (LVT), and rubber flooring that specializes in carbon-neutral and sustainable flooring solutions. Why Are We Out on TILE? Sales stagnated over the last five years and signal the need for new growth strategies Performance over the past five years shows each sale was less profitable, as its earnings per share fell by 3.5% annually Below-average returns on capital indicate management struggled to find compelling investment opportunities At $20.97 per share, Interface trades at 7.6x forward EV-to-EBITDA. If you're considering TILE for your portfolio, see our FREE research report to learn more. Rolling One-Year Beta: 0.74 Often located in suburban or semi-rural shopping centers, Ollie's Bargain Outlet (NASDAQ:OLLI) is a discount retailer that acquires excess inventory then sells at meaningful discounts. Why Is OLLI on Our Radar? Aggressive strategy of rolling out new stores to gobble up whitespace is prudent given its same-store sales growth Same-store sales growth averaged 4.1% over the past two years, showing it's bringing new and repeat shoppers into its stores Market share is on track to rise over the next 12 months as its 14.1% projected revenue growth implies demand will accelerate from its six-year trend Ollie's is trading at $112.16 per share, or 29.7x forward P/E. Is now the right time to buy? See for yourself in our comprehensive research report, it's free. Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Journals
15-05-2025
- Business
- Business Journals
Crash diet
New drugs like Ozempic have cut into Medifast's customer base, with the firm losing tens of thousands of coaches and millions of dollars in revenue.
Yahoo
29-04-2025
- Business
- Yahoo
Herbalife (HLF) Q1 Earnings: What To Expect
Health and wellness products company Herbalife (NYSE:HLF) will be announcing earnings results tomorrow afternoon. Here's what to expect. Herbalife beat analysts' revenue expectations by 0.6% last quarter, reporting revenues of $1.21 billion, flat year on year. It was a strong quarter for the company, with an impressive beat of analysts' EPS estimates and a solid beat of analysts' EBITDA estimates. Is Herbalife a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Herbalife's revenue to decline 2.8% year on year to $1.23 billion, a deceleration from its flat revenue in the same quarter last year. Adjusted earnings are expected to come in at $0.41 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Herbalife has missed Wall Street's revenue estimates three times over the last two years. Looking at Herbalife's peers in the consumer staples segment, some have already reported their Q1 results, giving us a hint as to what we can expect. USANA delivered year-on-year revenue growth of 9.5%, beating analysts' expectations by 2.7%, and Medifast reported a revenue decline of 33.8%, falling short of estimates by 0.6%. USANA traded up 5.2% following the results. Read our full analysis of USANA's results here and Medifast's results here. The outlook for 2025 remains clouded by potential trade policy changes and corporate tax discussions, which could impact business confidence and growth. While some of the consumer staples stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.4% on average over the last month. Herbalife is down 20% during the same time and is heading into earnings with an average analyst price target of $9.33 (compared to the current share price of $6.90). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Sign in to access your portfolio
